Cognitive Impairment Associated with Cancer: A Brief Review
CONCLUSION Cognitive impairment can affect daily functioning, quality of life, and capacity to work in patients with cancer and those in remission. Consequently, cognitive assessment is now an important and necessary part of a comprehensive oncological care plan. Cancer-related cognitive impairment might be due to the direct effects of the cancer itself, nonspecific factors, or comorbid conditions that are independent of the disease and/or due to the adverse effects of the treatment or combination of treatments given for the disease. The prevalence and extent of cognitive impairment associated with cancer is recognized but not well understood due, in part, to marked differences in the research methods and definitions used for evaluating cognitive functioning in these patients. Most studies have identified attention, memory, and information processing as the most frequent cognitive domains impacted by cancer and cancer-related treatments, but further research clearly is needed. Recent efforts have been made to develop common definitions to define cognitive impairment in cancer patients and to suggest guidelines for the most appropriate cognitive tests to be used. Cognitive function has increasingly been recognized as a requisite therapeutic target in many diseases, including cancer. The extent of cognitive impairment that is observed in patients with cancer and those in remission make cognitive functioning a particularly important target for clinical trials and clinical practi...
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Yanhua Liu, Yang Li, Shanshan Dong, Lu Han, Ruixin Guo, Yourong Fu, Shenghu Zhang, Jianqiu Chen
Publication date: Available online 9 October 2020Source: Journal of Hazardous MaterialsAuthor(s): Xiang Chen, Yihan Dai, Jin Fan, Xiaoyun Xu, Xinde Cao
Publication date: Available online 30 September 2020Source: Journal of Hazardous MaterialsAuthor(s): Anthony Beauvois, Delphine Vantelon, Jacques Jestin, Martine Bouhnik-Le Coz, Charlotte Catrouillet, Valérie Briois, Thomas Bizien, Mélanie Davranche
We describe the most highly recommended generic and disease-specific PRO tools in SCD and discuss the challenges of incorporating them in clinical practice. EXPERT OPINION: PRO measures are essential to incorporate into SCD clinical trials either as primary or secondary outcomes. The use of PRO measures in SCD facilitates a patient-centered approach, which is likely to lead to improved outcomes. Significant challenges remain in adapting PRO tools to routine clinical use and in developing countries. PMID: 33034214 [PubMed - as supplied by publisher]
Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the e...
Publication date: January 2021Source: Urology Case Reports, Volume 34Author(s): Nina Al-Saadi, Safa Al-Musawi, Yousuf Khan, Daben Dawam
Publication date: Available online 10 October 2020Source: European UrologyAuthor(s): Stanley Weng, Renzo G. DiNatale, Andrew Silagy, Roy Mano, Kyrollis Attalla, Mahyar Kashani, Kate Weiss, Nicole E. Benfante, Andrew G. Winer, Jonathan A. Coleman, Victor E. Reuter, Paul Russo, Ed Reznik, Satish K. Tickoo, A. Ari Hakimi
Publication date: Available online 10 October 2020Source: European Journal of Surgical OncologyAuthor(s): Tetsutaro Miyoshi, Satoshi Yamaguchi, Hiroshi Fujimoto, Shigeru Yoshioka, Masayuki Shiobara, Kazuo Wakatsuki, Kosuke Suda, Kotaro Miyazawa, Toshiaki Aida, Yoshihiro Watanabe, Masayuki Ohtsuka
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia | Amnesia | Antidoxidants | Anxiety | AstraZeneca | Avonex | Back Pain | Biotechnology | Brain | Brain Cancers | Brain Tumor | Breast Cancer | Breast Carcinoma | Cambridge University | Cancer | Cancer & Oncology | Cancer Therapy | Carcinoma | Chemotherapy | Child Development | Childhood Cancer | Children | Chronic Leukemia | Chronic Lymphocytic Leukemia | Chronic Pain | Clinical Trials | Colorectal Cancer | Computers | Concerta | Dementia | Depression | Disability | Docetaxel | Donepezil | Drugs & Pharmacology | Employment | Endocrine Therapy | Epidemiology | Epithelial Cancer | Gastroschisis Repair | Genetics | Geriatrics | Glioma | Headache | Health Management | Iron | Learning | Legislation | Leukemia | Lung Cancer | Lymphoma | Men | Menopause | Merck | Methotrexate | Methylphenidate | Middle East Health | Migraine | Mitochondrial Disease | Modafinil | MRI Scan | Myelodysplastic Syndrome | Myeloma | Namenda | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Netherlands Health | Neurology | Neuroscience | Neurosurgery | Nutrition | Occupational Health | Occupational Therapy | Ovarian Cancer | Ovaries | Oxford University | Pain | Pain Management | Pathology | Pediatrics | Pfizer | Pharmaceuticals | Primary CNS Lymphoma | Provigil | Psychiatry | Psychology | Radiation Therapy | Rebif | Rehabilitation | Ritalin | Science | Sleep Disorders | Sleep Medicine | Statistics | Study | Tamoxifen | Taxotere | Testicular Cancer | Toxicology | Training | UK Health | Universities & Medical Training | Women | Workshops